Clinical Trial Update: Clinical Study of Recombinant Mycobacterium Tuberculosis ESAT6-CFP10 Allergen [Phase 3]

View source ↗

Summary

A Phase 3 clinical study evaluating a recombinant ESAT6-CFP10 allergen for tuberculosis has completed, according to ClinicalTrials.gov.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tuberculosis

Drugs mentioned

• ESAT6-CFP10 recombinant allergen vaccine (ESAT6-CFP10 allergen)

Snippet

Sponsor: Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | Conditions: Tuberculosis | Phase 3 | Status: COMPLETED